Significant reductions in HBeAg from baseline were achieved in all treatment groups 24 weeks posttreatment ; reductions were comparable across treatment arms ( shown as log10 Paul Ehrlich international units [ PEIU ] / mL ) : monotherapy : -1.4 ( SD , 1.8 ) ; ETV add-on : -1.6 ( SD , 1.8 ) ; ETV pretreatment : -1.3 ( SD , 1.7 ) .